IPM514 + tislelizumab

IPM514 + tislelizumab is an investigational combination therapy being studied primarily for esophageal squamous cell carcinoma. IPM514 is a novel agent (details on its precise modality and mechanism are not yet publicly available), while tislelizumab is a humanized IgG4 monoclonal antibody targeting programmed cell death protein 1 (PD-1). Tislelizumab blocks the interaction between PD-1 and its ligands PD-L1/PD-L2, thereby restoring T-cell function and promoting immune-mediated antitumor activity. The combination is under evaluation in open-label, multicenter clinical trials that include dose escalation (IPM514 monotherapy), dose expansion (IPM514 with anti-PD-1 antibody), and neoadjuvant cohorts (adding cisplatin and paclitaxel). The primary indication under investigation is esophageal squamous cell carcinoma, both in advanced/metastatic settings after failure of first-line therapy and as neoadjuvant treatment for resectable disease[2][3][4].